­ Argenica Therapeutics Limited advised that Dr. Samantha South will not seek re-election at the upcoming 2023 Annual General Meeting (AGM) and will resign as an Executive Director, effective at the conclusion of the AGM on 30 November 2023. Dr. South will continue in her executive capacity
as Vice President of Non-Clinical Development at the Company. Dr. South has been a founding Director of Argenica and played an instrumental role in the development of Argenica's intellectual property over many years whilst at the University of Western Australia and following its assignment to Argenica in 2020. In her capacity as an Executive Director at Argenica, Dr. South has played a pivotal role in managing the preclinical activities of the Company, culminating in Argenica progressing to its Phase 1 and Phase 2 clinical trials. Going forward, Dr. South will continue to play a key executive role in the Company managing the Company's pipeline development and ongoing non-clinical activities across multiple therapeutic conditions.